Stock Events

Stock Events

Nanobiotix 

$30.97
152
+$0.38+1.25% Today

Statistics

Day High
30.97
Day Low
29.65
52W High
41.89
52W Low
3.12
Volume
37,397
Avg. Volume
46,422
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31MarExpected
Q1 2023
Q2 2023
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Q4 2025
-1.73
-1.05
-0.38
0.3
Expected EPS
0.29950005
Actual EPS
-0.4580589

Financials

595.8%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
-23.81MRevenue
-141.84MNet Income

Analyst Ratings

$36.00Average Price Target
The highest estimate is 36.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NBTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech company that develops innovative therapies, including for cancer, which competes with Nanobiotix's focus on nanomedicine for oncology.
Merck
MRK
Mkt Cap298.84B
Merck is a global healthcare company that produces cancer treatments, directly competing with Nanobiotix's cancer-focused nanotherapeutics.
Novartis
NVS
Mkt Cap297.32B
Novartis is involved in the research and development of novel healthcare solutions, including cancer treatments, making it a competitor in the oncology space.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and manufactures drugs and vaccines, including for cancer, competing with Nanobiotix's oncology innovations.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that develops cancer therapies, competing with Nanobiotix's approach to cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is a global biopharmaceutical company focusing on cancer drugs, competing with Nanobiotix's cancer treatment technologies.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals focuses on developing biopharmaceutical treatments, including for cancer, making it a competitor to Nanobiotix.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in creating new therapies, including for serious diseases potentially overlapping with Nanobiotix's target areas.

About

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Show more...
CEO
Mr. Laurent Levy Ph.D.
Employees
108
Country
US
ISIN
US63009J1079

Listings

STU
DE
5NR.STU
STU
DE
5NRA.STU
F
DE
5NRA.F
PA
FR
NANO.PA

0 Comments

Share your thoughts

FAQ

What is Nanobiotix stock price today?▼
The current price of NBTX is $30.97 USD — it has increased by +1.25% in the past 24 hours. Watch Nanobiotix stock price performance more closely on the chart.
What is Nanobiotix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nanobiotix stocks are traded under the ticker NBTX.
Is Nanobiotix stock price growing?▼
NBTX stock has fallen by -0.22% compared to the previous week, the month change is a -19.86% fall, over the last year Nanobiotix has showed a +874.61% increase.
When is the next Nanobiotix earnings date?▼
Nanobiotix is going to release the next earnings report on September 30, 2026.
What were Nanobiotix earnings last quarter?▼
NBTX earnings for the last quarter are -0.46 USD per share, whereas the estimation was 0.3 USD resulting in a -252.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nanobiotix revenue for the last year?▼
Nanobiotix revenue for the last year amounts to -23.81M USD.
What is Nanobiotix net income for the last year?▼
NBTX net income for the last year is -141.84M USD.
How many employees does Nanobiotix have?▼
As of April 10, 2026, the company has 108 employees.
In which sector is Nanobiotix located?▼
Nanobiotix operates in the Health Care sector.
When did Nanobiotix complete a stock split?▼
Nanobiotix has not had any recent stock splits.
Where is Nanobiotix headquartered?▼
Nanobiotix is headquartered in Paris, US.